Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gumarontinib
- Development stage
- Phase 2
- Lead developer
- Haihe
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gumarontinib (also known as glumetinib or SCC-244) is an oral, potent, and highly selective small-molecule inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase. Co-developed by the Shanghai Institute of Materia Medica (SIMM) and Haihe Biopharma, gumarontinib is designed to target MET alterations, such as MET exon 14 skipping mutations and MET protein overexpression, which act as key oncogenic drivers in non-small cell lung cancer (NSCLC). It has demonstrated robust antitumor activity, a favorable pharmacokinetic profile with a long half-life allowing for once-daily dosing, and blood-brain barrier penetration, making it effective against central nervous system metastases. Gumarontinib received conditional approval in China in March 2023 and full approval in Japan in June 2024 for the treatment of advanced or recurrent MET-mutant NSCLC.
- Brand names
- Haiyitan
- Other names
- Gematinibglumetinibgumeitimigumeitinigumetinib
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on gumarontinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gumarontinib.